Skip to main content

Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis

PharmacoEconomics volume 28, pages 477–487 (2010)Cite this article

Abstract

Background: The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This article seeks to understand these differences using a cohort of patients with inflammatory arthritis.

Objective: To examine the relationship between the disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, SF-6D, EQ-5D and European League Against Arthritis (EULAR) Disease Activity Score (DAS) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Methods: Patients with RA and PsA (n = 504) attending a tertiary rheumatology referral centre completed the HAQ, SF-6D and the EQ-5D before starting biological therapy and again 12 months later. The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such as the DAS, joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis to derive a mapping function and calculated utility scores from the HAQDI and the DAS 28.

Results: The mean utility observed at baseline for RA was 0.43 for the EQ-5D and 0.54 for the SF-6D and for PsA was 0.49 for the EQ-5D and 0.57 for the SF-6D. The utility gain demonstrated by the EQ-5D was over twice that of the SF-6D. The EQ-5D scored 17% of the RA group as less than 0 (state defined as worse than death); 7% of this group remained less than 0 at followup. The distribution of the utility estimates was similar for both RA and PsA.

Conclusions: Our findings draw attention to the impact of states worse than death on the overall distribution for the EQ-5D derived utilities and how these impact on its use in practice. EQ-5D-derived QALY changes are over twice that of the SF-6D. The implication of this for decision makers is that cost-effectiveness evaluations for treatments in this disease class are likely to be very sensitive to the choice of utility measure.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Fig. 1
Fig. 2
Fig. 3

References

  1. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. The National Arthritis Data Work Groups. Arthritis Rheum 1995; 38 (10): 1351–62

    PubMed  Article  CAS  Google Scholar 

  2. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008; 26 (2): 121–9

    PubMed  Article  Google Scholar 

  3. van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39 (1): 34–40

    PubMed  Article  Google Scholar 

  4. Hurst N, Jobanputra P, Hunter M, et al. Validity of Euro-QoL: a generic health status instrument in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Rheumatology (Oxford) 1994; 33 (7): 655–62

    Article  CAS  Google Scholar 

  5. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    PubMed  Article  Google Scholar 

  6. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcomes in arthritis. Arthritis Rheum 1980; 23: 137–45

    PubMed  Article  CAS  Google Scholar 

  7. Bryan S, Longworth L. Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ 2005; 6 (3): 253–60

    PubMed  Article  Google Scholar 

  8. Seymour J, McNamee P, Scott A, et al. Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ-5D and SF-6D responses. Health Econ. Epub 2009 Jun 5

    Google Scholar 

  9. Lamers L, Bouwmans C, van Straten A, et al. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 2006; 15 (11): 1229–36

    PubMed  Article  CAS  Google Scholar 

  10. Gerard K, Nicholson T, Mullee M, et al. EQ-5D versus SF- 6D in an older, chronically ill patient group. Appl Health Econ Health Policy 2004; 3 (2): 91–102

    PubMed  Article  Google Scholar 

  11. Kobelt G, Lindgren P, Lindroth Y, et al. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (9): 1169–75

    Article  CAS  Google Scholar 

  12. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56

    PubMed  Article  CAS  Google Scholar 

  13. Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004; 43 (1): 62–72

    Article  CAS  Google Scholar 

  14. Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004; 8 (11): iii, 1–91

    Google Scholar 

  15. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64 (7): 995–1002

    PubMed  Article  CAS  Google Scholar 

  16. Tanno M, Nakamura I, Ito K, et al. Modeling and costeffectiveness analysis of etanercept in adultswith rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006; 16 (2): 77–84

    PubMed  Article  Google Scholar 

  17. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008

    Google Scholar 

  18. Bansback N, Marra C, Tsuchiya A, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Care Res 2007; 57 (6): 963–71

    Article  Google Scholar 

  19. Harrison MJ, Lunt M, Bansback N, et al. The validity of estimating EQ-5D and SF-6D utility values from the HAQ. American College of Rheumatology Annual Meeting; 2008 Oct 24-29; San Francisco (CA)

    Google Scholar 

  20. Barton GR, Sach TH, Jenkinson C, et al. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008; 6: 51

    PubMed  Article  Google Scholar 

  21. Craig BM, Busschbach JJ. The episodic random utility model unifies time trade-off and discrete choice approaches in health state valuation. Popul Health Metr 2009; 7: 3

    PubMed  Article  Google Scholar 

  22. van Riel P, van Gestel A, van de Putte L. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996; 35 Suppl. 2: 4–7

    PubMed  Article  Google Scholar 

  23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21 (2): 271–92

    PubMed  Article  Google Scholar 

  24. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005

    Google Scholar 

  25. Kharroubi S, Brazier JE, O’Hagan A. Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method. Soc Sci Med 2007; 64 (6): 1242

    PubMed  Article  Google Scholar 

  26. University of Sheffield, Health Economics and Decision Science. Bayesian programme [online]. Available from URL: http://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d/bayesian.html [Accessed 2009 Dec 1]

  27. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010 Jan; 69 (1): 222–5

    PubMed  Article  CAS  Google Scholar 

  28. Lindgren P, Geborek P, Kobelt G. Modelling the costeffectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009; 25 (02): 181–9

    PubMed  Article  Google Scholar 

  29. Hurst N, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology (Oxford) 1997; 36 (5): 551–9

    Article  CAS  Google Scholar 

  30. Marra C, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004; 42 (11): 1125–31

    PubMed  Article  Google Scholar 

  31. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996; 5 (2): 141–54

    PubMed  Article  CAS  Google Scholar 

  32. EQ-5D: a standardised instrument for use as a measure of health outcome [online]. Available from URL: http://www.euroqol.org [Accessed 2009 Sep 1]

  33. Fries J, Spitz P, Young D. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9 (5): 789–93

    PubMed  CAS  Google Scholar 

  34. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 1994

    Google Scholar 

  35. Pharmaceutical Benefits Board. General guidelines for economic evaluation from the Pharmaceutical Benefits Board. 2003 [online]. Available from URL: http://www.tlv.se [Accessed 2010 Feb 23]

    Google Scholar 

  36. Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes: a Spanish proposal for methodological standardisation. Pharmacoeconomics 1995; 8 (3): 245–52

    PubMed  Article  CAS  Google Scholar 

  37. The AMCP Format for Formulary Submissions (version 3.0). Alexandria (VA): Foundation for Managed Care Pharmacy, 2009 Oct

  38. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-a inhibitors in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. An independent report. Rheumatology (Oxford) 2007; 46: 1345–54

    Article  CAS  Google Scholar 

  39. Harrison MJ, Davies LM, Bansback NJ, et al. Why do patients with inflammatory arthritis often score states ‘worse than death’ on the EQ-5D? An investigation of the EQ-5D classification system. Value Health 2009 Sep; 12 (6): 1026–34

    PubMed  Article  Google Scholar 

  40. Marra CA, Rashidi AA, Guh D, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005; 14 (5): 1333

    PubMed  Article  Google Scholar 

  41. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference- based instruments. Med Care 2003; 41 (7): 791–801

    PubMed  Article  Google Scholar 

  42. Harrison MJ, Davies LM, Bansback NJ, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009 Nov; 18 (9): 1195–205

    PubMed  Article  CAS  Google Scholar 

  43. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001; 45 (2): 151–8

    Article  CAS  Google Scholar 

  44. Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006; 45 (8): 1029–38

    Article  CAS  Google Scholar 

  45. Kielhorn A, Porter D, Diamantopoulos A, et al. UK costutility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008; 24 (9): 2639–50

    PubMed  Article  CAS  Google Scholar 

  46. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781–96

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

No funding was received for this study.

Professor Veale has received research grants from Wyeth Pharmaceuticals, Schering Plough and GlaxoSmithKline, and consulting fees from Wyeth Pharmaceuticals and Schering Plough. Professor FitzGerald has received a research grant from Abbott Immunology Pharmaceuticals and is a speaker for Wyeth Pharmaceuticals, Abbott Immunology Pharmaceuticals and Bristol Myers Squibb.

The authors thank Dr C.T. Ng, Dr Adrian Gibbs, Dr Bernadette Lynch and Dr Tajvur Saber for their assistance in collecting these data.

Author information

Affiliations

  1. National Centre for Pharmacoeconomics, St. James’ Hospital, St. James’ Street, Dublin 8, Ireland

    Roisin Adams, Cathal Walsh & Michael Barry

  2. Department of Statistics, Trinity College Dublin, Dublin, Ireland

    Cathal Walsh

  3. St. Vincent’s University Hospital, Dublin Academic Healthcare, Dublin, Ireland

    Douglas Veale, Barry Bresnihan & Oliver FitzGerald

Authors
  1. Roisin Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathal Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Veale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barry Bresnihan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oliver FitzGerald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roisin Adams.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Adams, R., Walsh, C., Veale, D. et al. Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. Pharmacoeconomics 28, 477–487 (2010). https://doi.org/10.2165/11533010-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533010-000000000-00000

Keywords

  • Rheumatoid Arthritis
  • Inflammatory Arthritis
  • Biological Therapy
  • Utility Score
  • Disease Activity Score